Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
T Jakob, YM Tesfamariam, S Macherey… - Cochrane Database …, 2020 - cochranelibrary.com
Background Different bone‐modifying agents like bisphosphonates and receptor activator of
nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men …
nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men …
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis
T Jakob, YM Tesfamariam… - The Cochrane …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Different bone-modifying agents like bisphosphonates and receptor activator of
nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men …
nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men …
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
T Jakob, YM Tesfamariam, S Macherey… - The Cochrane …, 2020 - europepmc.org
Background Different bone-modifying agents like bisphosphonates and receptor activator of
nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men …
nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men …
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
T Jakob, YM Tesfamariam, S Macherey… - Cochrane Database …, 2020 - cochranelibrary.com
Background Different bone‐modifying agents like bisphosphonates and receptor activator of
nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men …
nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men …
[HTML][HTML] Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis
T Jakob, YM Tesfamariam, S Macherey… - Cochrane Database of …, 2020 - hero.epa.gov
BACKGROUND: Different bone-modifying agents like bisphosphonates and receptor
activator of nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive …
activator of nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive …
[HTML][HTML] Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
T Jakob, YM Tesfamariam, S Macherey… - The Cochrane …, 2020 - ncbi.nlm.nih.gov
Background Different bone‐modifying agents like bisphosphonates and receptor activator of
nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men …
nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men …
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
T Jakob, YM Tesfamariam, S Macherey… - The Cochrane …, 2020 - europepmc.org
Background Different bone-modifying agents like bisphosphonates and receptor activator of
nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men …
nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men …